Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > LATEST
LATEST
-
BUSINESS ASKA to Boost Stake in Vietnam’s Ha Tay for Generic Biz Base
February 4, 2025
-
BUSINESS Dato-DXd Gets EU Panel Backing for Breast Cancer: Daiichi Sankyo
February 4, 2025
-
BUSINESS Daiichi Sankyo, Takeda Restricting Shipments of Mumps Vaccines
February 3, 2025
-
REGULATORY Council OKs Public Knowledge Application for CellCept Label Expansion
February 3, 2025
-
REGULATORY LDP OKs Govt’s 5-Year Healthcare Strategy with “Expanding Ecosystems” as Main Pillar
February 3, 2025
-
BUSINESS Sumitomo Ups FY2024 Earnings Outlook, Now Expects Black Ink
February 3, 2025
-
BUSINESS Shionogi to Bolster New Drug Development in China
February 3, 2025
-
BUSINESS Daiichi Sankyo Assigns COO Okuzawa as CEO from April
February 3, 2025
-
BUSINESS Datroway Now in PIII Study for Adjuvant NSCLC Setting: Daiichi Sankyo
February 3, 2025
-
REGULATORY Lixiana Now Set for Label Expansion; 11 Drugs to Get Orphan Tags
February 3, 2025
-
BUSINESS Daiichi Sankyo to Promote COO Okuzawa to CEO
January 31, 2025
-
BUSINESS Sarepta Drops DMD Drug Patent Claim against Nippon Shinyaku in Japan
January 31, 2025
-
BUSINESS Novo Launches Once-Weekly Insulin Awiqli in Japan
January 31, 2025
-
REGULATORY CSL’s HAE Drug, Tecentriq Sarcoma Use Clear Panel Review; February Approval Expected
January 31, 2025
-
BUSINESS J&J Files Nipocalimab for Generalized Myasthenia Gravis in Japan
January 31, 2025
-
BUSINESS Chugai Logs Record Earnings in 2024 on Upbeat Exports to Roche
January 31, 2025
-
BUSINESS Chugai, SoftBank in AI Deal to Speed Up Drug Development
January 31, 2025
-
BUSINESS Chugai, GSK Join Hands in Anti-Dengue Antibody Development
January 31, 2025
-
BUSINESS Takeda Drops Epilepsy Med Soticlestat after PIII Miss
January 31, 2025
-
BUSINESS Takeda Ups Full-Year Guidance on Slower Vyvanse Generic Erosion
January 31, 2025
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…